Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03149029 · ClinicalTrials.gov registry record · Phase 2

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

A Phase 2 study of Metastatic Melanoma, sponsored by Massachusetts General Hospital.

Active
Registry status
Phase 2
Development phase
16
Enrollment target
3
Study locations

NCT03149029 is a Phase 2 study of Metastatic Melanoma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03149029, a Phase 2 study of Metastatic Melanoma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
16 participants
Enrollment target
3
Study locations

Study Summary

This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: * Pembrolizumab (Keytruda) * Trametinib (Mekinist) * Dabrafenib (Tafinlar)

Conditions Studied

Metastatic Melanoma

Interventions

  • DRUG Pembrolizumab
  • DRUG Trametinib
  • DRUG Dabrafenib

Study Locations (3)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Massachusetts general Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2017-11-27
Est. Completion 2025-12-31
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03149029

The ClinicalTrials.gov registry entry for NCT03149029 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (81% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT03149029 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03149029 about?

NCT03149029 is a clinical study titled "Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma". This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: * Pembrolizumab (Keytruda) * Trametinib (Mekinist) * Dabrafenib (Tafinlar)

What is the current status of trial NCT03149029?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-11-27. Estimated completion is 2025-12-31.

What conditions does trial NCT03149029 study?

This clinical trial studies the following conditions: Metastatic Melanoma.

What interventions are being tested in trial NCT03149029?

The interventions under investigation include: Pembrolizumab (DRUG), Trametinib (DRUG), Dabrafenib (DRUG).

Who is sponsoring clinical trial NCT03149029?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03149029 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Melanoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.